TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03489213

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional Intervention
Description: Participants randomized to the beef group will receive 11 to 18 ounces of frozen lean beef each week for home preparation, in addition to DGA/AICR diet education, garden access and health coaching.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional Intervention
Description: Participants randomized to the beef group will receive 11 to 18 ounces of frozen lean beef each week for home preparation, in addition to DGA/AICR diet education, garden access and health coaching.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT00599651

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surfactant administered via Laryngeal Mask Airway (LMA)
Description: Standard volume of Infasurf surfactant (3 mL/kg) will be injected in 2-4 aliquots into the proximal end of the LMA.

Intervention type: OTHER
Group type: OTHER
Intervention: standard of care (nasal CPAP and supplemental oxygen)
Description: Standard of care will be utilized which may mean surfactant is administered
Study: NCT03114761

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CT angiography
Description: Patients are subjected to a standard abdominal CT scan and (additional in this study) to abdominal CT angiography (CTA)
Study: NCT03991637

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Invasive Comprehensive Metabolic Panel
Description: The device utilizes spectroscopy and machine learning to detect metabolic analyte concentrations.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-Invasive Comprehensive Metabolic Panel
Description: The device utilizes spectroscopy and machine learning to detect metabolic analyte concentrations.
Study: NCT02317731

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Straw
Description: Bowel preparation ingestion with a straw
Study: NCT03216616

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Study: NCT00479466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0893
Description: MK0893 taken orally once daily; 20 mg and 40 mg tablets used in combination according to dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0893
Description: MK0893 taken orally once daily; 20 mg and 40 mg tablets used in combination according to dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0893
Description: MK0893 taken orally once daily; 20 mg and 40 mg tablets used in combination according to dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0893
Description: MK0893 taken orally once daily; 20 mg and 40 mg tablets used in combination according to dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin HCL 500 mg tablet twice daily titrating up to 1000 mg twice daily over 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to MK0893
Description: Dose-matched placebo tablets to MK0893; taken orally once daily.
Study: NCT03294213

Intervention type: DEVICE
Intervention: aScope 4 Broncho
Description: Investigator is asked: In your memory, compare your daily bronchoscope and the aScope 4 Broncho just evaluated on patients admitted to the OR or ICU undergoing at least one bronchoscopy procedure Patients will not be asked to consent to participate in this study, as no patient data are obtained and the CE-marked aScope™ 4 Broncho is used within its intended use
Study: NCT00479466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to MK0893
Description: Dose-matched placebo tablets to MK0893; taken orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to MK0893
Description: Dose-matched placebo tablets to MK0893; taken orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to MK0893
Description: Dose-matched placebo tablets to MK0893; taken orally once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to MK0893
Description: Dose-matched placebo tablets to MK0893; taken orally once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to MK0893
Description: Dose-matched placebo tablets to MK0893; taken orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Metformin
Description: Dose-matched placebo tablets to metformin (500 mg); taken orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Metformin
Description: Dose-matched placebo tablets to metformin (500 mg); taken orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Metformin
Description: Dose-matched placebo tablets to metformin (500 mg); taken orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Metformin
Description: Dose-matched placebo tablets to metformin (500 mg); taken orally twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Metformin
Description: Dose-matched placebo tablets to metformin (500 mg); taken orally twice daily.
Study: NCT03426059

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention. This is an observational study.
Study: NCT00804856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volasertib
Description: Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volasertib
Description: Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).
Study: NCT01078753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin
Description: Desmopressin oral lyophilisate tablet, 120 μg or 240 μg, administered sublingually once a day 1½ hours before bedtime.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral lyophilisate tablet was administered sublingually once a day 1½ hours before bedtime.
Study: NCT03543371

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological assessment
Description: Standardized neuropsychological battery consisting of the following tests and questionnaires: Wechsler Adult Intelligence Scale - Fourth Edition (WAIS-IV) Vocabulary, Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency, WAIS-IV Block Design, WAIS-IV Matrix Reasoning, WAIS-IV Digit Span, Wechsler Memory Scale - Third Edition (WMS-III) Spatial Span, Rey Auditory Verbal Learning Test (RAVLT), WMS-III Logical Memory, Brief Visuospatial Memory Test-Revised (BVMT-R), Trail Making Test (TMT) A \& B, D-KEFS Color Word Interference Test, Behavioral Assessment of the Dysexecutive Syndrome Dysexecutive Questionnaire (BADS DEX), Multidimensional Fatigue Inventory (MFI-20), Minimal Insomnia Symptom Scale (MISS), Hospital Anxiety and Depression Scale (HADS).

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological assessment
Description: Standardized neuropsychological battery consisting of the following tests and questionnaires: Wechsler Adult Intelligence Scale - Fourth Edition (WAIS-IV) Vocabulary, Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency, WAIS-IV Block Design, WAIS-IV Matrix Reasoning, WAIS-IV Digit Span, Wechsler Memory Scale - Third Edition (WMS-III) Spatial Span, Rey Auditory Verbal Learning Test (RAVLT), WMS-III Logical Memory, Brief Visuospatial Memory Test-Revised (BVMT-R), Trail Making Test (TMT) A \& B, D-KEFS Color Word Interference Test, Behavioral Assessment of the Dysexecutive Syndrome Dysexecutive Questionnaire (BADS DEX), Multidimensional Fatigue Inventory (MFI-20), Minimal Insomnia Symptom Scale (MISS), Hospital Anxiety and Depression Scale (HADS).
Study: NCT01772134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umeclidinium bromide 62.5mcg
Description: Inhalation Powder, LAMA 62.5mcg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Umeclidinium bromide 125mcg
Description: Inhalation Powder, LAMA 125mcg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluticasone propionate 250mcg/Salmeterol 50mcg
Description: Inhalation Powder, ICS/LABA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate 250mcg/Salmeterol 50mcg
Description: Inhalation Powder, ICS/LABA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 250mcg/Salmeterol 50mcg
Description: Inhalation Powder, ICS/LABA

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhalation Powder, Placebo
Study: NCT03716791

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: methylsulfonylmethane
Description: 3g per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: white rice flour
Study: NCT04339504

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SMUP-IA-01(low-dose)
Description: A single knee administration of SMUP-IA-01(low-dose, 4.0 x 10\^6 cells/2mL)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SMUP-IA-01(mid-dose)
Description: A single knee administration of SMUP-IA-01(mid-dose, 1.0 x 10\^7 cells/2mL)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SMUP-IA-01(high-dose)
Description: A single knee administration of SMUP-IA-01(high-dose, 2.0 x 10\^7 cells/2mL)
Study: NCT00804856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volasertib
Description: Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.
Study: NCT01704885

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Play Intervention
Study: NCT01676194

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intra-arterial administration of DC BeadsR
Study: NCT01704885

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Questionnaires
Study: NCT03138967

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: Experimental: Sugammadex Participants to have cystoscopy with bladder tumor resection. Rocuronium used to induce the neuromuscular blockade and given in a rapid sequence for endotracheal intubation at a dose of 0.45 mg/kg of Ideal Body Weight. If maintenance is needed for continued relaxation then a dose of 0.15 mg/kg of Ideal Body Weight repeated as necessary.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Experimental: Sugammadex Participants to have cystoscopy with bladder tumor resection. Rocuronium used to induce the neuromuscular blockade and given in a rapid sequence for endotracheal intubation at a dose of 0.45 mg/kg of Ideal Body Weight. If maintenance is needed for continued relaxation then a dose of 0.15 mg/kg of Ideal Body Weight repeated as necessary.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Sugammadex administered as a single bolus, intravenous injection. The amount used is based on the patient's weight. A dose of 4 mg/kg used if recovery has reached at least 1-2 post-tetanic counts (PTC) following Rocuronium induced blockade.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: 70 mcg/kg by vein to reverse the muscle relaxation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycopyrrolate
Description: 14 mcg/kg by vein to reverse the muscle relaxation.
Study: NCT04376190

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low level laser therapy
Description: In the laser group, patients received LLLT from a semiconductor Gallium Aluminum Arsenide diode laser (SMARTMPRO, LASOTRONIX, Poland) with the following set parameters; 635 nm wavelength in continuous-wave mode, 50 mw power output, 4.5 J/cm2 energy density, 11.25 J total dose per side, 45 seconds/ point, and 8 mm fiber optic tip diameter. Laser was applied (Fig.2) at five points located within TMJ region on both right and left sides in contact with skin as follows: lateral, superior, anterior, posterior, and posterior- inferior points.
Study: NCT04736186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide
Description: Loperamide 4 mg， t.i.d.(d 1-7);4 mg, b.i.d.(d 8-21)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide
Description: Loperamide 4 mg， t.i.d.(d 1-7);4 mg, b.i.d.(d 8-21)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide
Description: Loperamide 4 mg， t.i.d.(d 1-7);4 mg, b.i.d.(d 8-21)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide and golden bifid
Description: Patients with secondary prevention will be randomly assigned to B：Loperamide 4 mg， t.i.d.(d 1-7);4 mg, b.i.d.(d 8-21)+golden bifid 2 g t.i.d.
Study: NCT01704885

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Study: NCT00893568

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resonance magnetic imaging (fMRI),
Description: a cerebral study will be performed at the neuroanatomic and functional levels by resonance magnetic imaging (fMRI) realized in three times (before, one week and six months after treatment)
Study: NCT04736186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide and montmorillonite powder
Description: Patients with secondary prevention will be randomly assigned to D：Loperamide 4 mg， t.i.d.(d 1-7);4 mg, b.i.d.(d 8-21)+montmorillonite powder 3 g t.i.d.
Study: NCT06558916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexketoprofen Trometamol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meperidine Injectable Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Patients with a VAS score of 40 mm or higher at the 30th minute were given fentanyl (1 mcg/kg, intravenously) as a rescue drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Patients with a VAS score of 40 mm or higher at the 30th minute were given fentanyl (1 mcg/kg, intravenously) as a rescue drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Patients with a VAS score of 40 mm or higher at the 30th minute were given fentanyl (1 mcg/kg, intravenously) as a rescue drug.
Study: NCT00893568

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resonance magnetic imaging (fMRI),
Description: a cerebral study will be performed at the neuroanatomic and functional levels by resonance magnetic imaging (fMRI) realized in three times (before, one week and six months after treatment)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: resonance magnetic imaging (fMRI),
Description: a cerebral study will be performed at the neuroanatomic and functional levels by resonance magnetic imaging (fMRI) realized in three times (before, one week and six months after treatment)
Study: NCT00835692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: 500 mg Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biaxin®
Description: 500 mg Tablet
Study: NCT04143022

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture press needle
Description: Press needle will be applied to acupoints at Jin's 3-tongue point ( EX-HN21 and the two extra channel points, 0.8 individual cun lateral to both sides of EX-HN21) and EX-HN25 in group A and at EX-CA1, EX-CA5 and EX-CA6 in group B. Each subject will start first course and receive the treatment 2 times a week for 4 weeks (8 times in total). Then, it takes 2-week washout period and make group A and group B crossover. Second course begins after 2-week washout period with the same treatment times as the first course.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture press needle
Description: Press needle will be applied to acupoints at Jin's 3-tongue point ( EX-HN21 and the two extra channel points, 0.8 individual cun lateral to both sides of EX-HN21) and EX-HN25 in group A and at EX-CA1, EX-CA5 and EX-CA6 in group B. Each subject will start first course and receive the treatment 2 times a week for 4 weeks (8 times in total). Then, it takes 2-week washout period and make group A and group B crossover. Second course begins after 2-week washout period with the same treatment times as the first course.
Study: NCT02680288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin, 10 mg
Description: Oral type 2C serotonergic agonist, low-dose
Study: NCT00377260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin-clavulanate
Description: Augmentin ES-600™: Amoxicillin-clavulanate potassium (600/42.9 mg per 5 mL), administered at a dose of 90/6.4 mg/kg/day in 2 divided doses for 10 days with strawberry cream flavor.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same base formulation of the licensed product Augmentin ES-600™, with the same strawberry cream flavor.
Study: NCT03526757

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standing Pilates protocol
Description: Subjects will be submitted to a bi-weekly, 50-minute session of Pilates exercises focusing on orthostatic position, for twelve weeks. The following equipment will be used: The Cadillac, Reformer and Chair, emphasizing balance training in the orthostatic position.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Pilates protocol
Description: Subjects will be submitted to a bi-weekly, 50-minute session of the standard sequence of Pilates exercises (traditional sequence of the contemporary / classical method) for twelve weeks. The exercises will be performed using the same equipment used in the intervention group, but following the dorsal decubitus, sedestation and orthostasis, in a time-balanced distribution in each session.
Study: NCT02680288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin, 20 mg
Description: Oral type 2C serotonergic agonist, high-dose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oral Placebo
Description: Oral inert treatment
Study: NCT01924377

Intervention type: PROCEDURE
Group type: OTHER
Intervention: standard circumferential pulmonary vein isolation by radiofrequency ablation catheter
Description: To perform circumferential pulmonary vein isolation left and right circumferential lines will be created with contiguous focal radiofrequency lesions at a distance \>5 mm from the pulmonary vein ostia. Two additional ablation lines will be performed in the posterior left atrium (LA), and an ablation line will be placed in the mitral isthmus to prevent postablation LA flutter. Patients with a history of typical atrial flutter will also undergo cavotricuspid isthmus ablation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CPVI + rotors' identification and ablation
Description: In CPVI + Rotor arm, two LA sequential maps will be collected before and after CPVI, respectively. During each map creation, rotor electrograms will be identified by the physician. Rotors will be ablated after collecting the second LA sequential map.
Study: NCT01890057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: The dose of sugammadex

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: The dose of sugammadex
Study: NCT01554007

Intervention type: OTHER
Intervention: Observation study
Description: No intervention was administered to the participants specifically for the purpose this study. Participant could be on any drug therapy.
Study: NCT01655654

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity
Description: This intervention includes cardiorespiratory exercise, resistance exercise, flexibility exercise and neuromotor exercise.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary
Description: Make at least one positive dietary change including or similar to a DASH diet snack substitution.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Primary care provider visit
Description: Subjects with hypertension will be asked to visit their primary care provider seeking treatment options. If a subject does not have a primary care provider then they will be encouraged to obtain one and seek medical treatment.
Study: NCT01895335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriflunomide
Description: Pharmaceutical form: film-coated tablet; Route of administration: oral
Study: NCT00191815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine (30 min intravenous infusion) dose of 1000mg/m2 on Day 1 and Day 8 (21 day cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Cisplatin (30-120 min intravenous infusion) dose of 35 mg/m2 on Day 1 and Day 8 (21 day cycle).
Study: NCT02982577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine
Description: Spray the basis of 1.54% pilocarpine, 3 times per day (each 8 hours), during 90 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Spray without Pilocarpine
Description: Spray without pilocarpine, 3 times per day (each 8 hours), during 90 days.
Study: NCT01294072

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No intervention
Description: no treatment